Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China

Figures & data

Table 1 The baseline characteristics of 29 patients were as follows

Characteristic	No. of patients	Percent
Age
Median (range)	58 (24–70)
<60	21	72.4
≥60	8	27.6
Sex
Male	17	58.6
Female	12	41.4
Histopathological type
PTCL-NOS	12	41.4
ALK- ALCL	9	31.0
AITL	7	24.1
EATL	1	3.4
Disease status
Relapse	11	37.9
Refractory	18	62.1
Stage
II	6	20.7
III	10	34.5
IV	13	44.2
Bone marrow involvement
Yes	5	17.2
No	24	82.8
B symptoms present
Yes	12	41.4
No	17	58.9
Serum LDH
Elevated	9	31.0
Normal	20	69.0
β2MG
Elevated	16	55.2
Normal	13	44.8
IPI
0–2	20	69.0
3–4	9	31.0
Prior chemotherapy regimen
CHOP	26	89.7
CHOPE	2	6.9
ESHAP	1	3.4

Abbreviations: PTCL-NOS, peripheral T-cell lymphoma, non-specific; ALK-ALCL, ALK-negative anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; LDH, serum lactate dehydrogenase; β2MG, β2microglobulin; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHOPE, CHOP+ etoposide; ESHAP, etoposide, cytarabine, cisplatin, methylprednisolone.

Table 2 Response to treatment between relapse patients and refractory patients

Response to treatment	Number of patients (n=29) (100%)		P
	Relapse patients	Refractory patients
(n=11)	(n=18)
End of treatment response
CR	4 (36.4)	6 (33.3)	0.589
PR	1 (9.0)	9 (50.0)
SD	2 (18.2)	2 (11.1)
PD	4 (10.0)	1 (5.6)
ORR (CR+PR)	5 (45.4)	15 (70.6)	0.048

Note: P: Fisher’s Exact Test.

Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.

Figure 1 Response rates of GDPT chemotherapy.

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; GDPT, gemcitabine, cisplatin, prednisone, and thalidomide.

Figure 2 Progression-free survival of GDPT with relapsed/refractory PLCL.Abbreviation: GDPT, gemcitabine, cisplatin, prednisone, and thalidomide.

Figure 3 Overall survival of GDPT with relapsed/refractory PLCL.

Abbreviation: GDPT, gemcitabine, cisplatin, prednisone, and thalidomide.

Table 3 Treatment-related toxicities

Toxicity	No. of patients	Percent
Hematologic toxicity
Leukopenia
Grade 1–2	18	62.1
Grade 3–4	11	37.9
Neutropenia
Grade 1–2	19	65.5
Grade 3–4	10	34.5
Anemia
Grade 1–2	22	75.9
Grade 3–4	7	24.1
Thrombocytopenia
Grade 1–2	20	69.0
Grade 3–4	9	31.0
Non-hematologic
Transaminase elevation	2	6.7
Creatinine elevation	0	0.0
Nausea and vomiting	10	34.5
Nerve damage	2	6.7
Drowsiness	5	17.2